Overview
- The Blood Advances analysis, published Tuesday, links self-reported Agent Orange exposure to a distinct genetic profile in myelodysplastic syndromes, a group of bone marrow cancers.
- Using the NHLBI MDS Natural History Study, which enrolled 2,115 patients with 130 reporting exposure, researchers found 54% of the exposed received an MDS or precursor diagnosis compared with 37% of the unexposed.
- Among patients with MDS, those exposed were more than twice as likely to carry high-risk chromosome changes tied to aggressive disease, and mutations such as TET2, SRSF2, U2AF1, ZRSR2 and KRAS appeared more often.
- Exposed veterans were diagnosed at a younger age and were about 80% more likely to see their disease worsen within two years of diagnosis.
- Researchers emphasize the study is observational and not proof of causation, yet they say the data could inform a VA review of whether to recognize MDS as an Agent Orange–related presumptive condition.